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Summary An analysis of the primary tumour histopathology was performed on 103 patients managed by
orchidectomy and surveillance for stage I seminoma. Patients have been followed for 14-141 months (median
62 months) after orchidectomy. Seventeen patients relapsed, the probability of remaining relapse free at 5
years being 82% (95% confidence intervals, 74%-88%). No patients died of progressive germ cell tumours.
The only significant histological factor predicting relapse was the presence of lymphatic and vascular invasion.
Four of 42 patients with neither lymphatic or vascular invasion recurred, nine of 53 patients with either
lymphatic or vascular invasion recurred and three of eight cases with both lymphatic and vascular invasion
recurred (P = 0.05-trend). Though initial recurrence was usually of moderate volume and confined to
para-aortic nodes, eight patients were treated with chemotherapy either because of the extent of their initial
relapse (four cases), or because of subsequent relapse (four cases). In view of the difficulties of identifying
patients at risk and of detecting early relapse, surveillance for stage I seminoma should remain a research
protocol.
The conventional management of stage I seminoma of the
testis is by adjuvant retroperitoneal node irradiation. This
policy is highly successful, recurrence occuring in less than
5% of patients (Hamilton et al., 1986; Zagars, 1991). Surveil-
lance following orchidectomy was introduced as an alterna-
tive with the rationale that a substantial proportion of
patients with stage I seminoma would not need further treat-
ment and could thus avoid the side-effects of radiotherapy.
This supposition was based partly on a series of retro-
peritoneal lymph node dissection in stage I seminoma, which
revealed microscopic nodal involvement in only 8% of
patients (Maier et al., 1968), and partly on the success of a
surveillance policy in stage I non-seminomatous tumours of
the testis (Freedman et al., 1987; Horwich & Peckham, 1988;
Cullen, 1991). Preliminary results of surveillance for stage I
seminomas have been reported (Thomas et al., 1989;
Duchesne et al., 1990) and it has become apparent that the
policy presents some clinical difficulties, such as for example,
the relatively indolent natural history of seminoma leading to
a requirement for prolonged surveillance. A second problem
is the lack of a sensitive serum marker for seminoma (in
contrast to non-seminoma) making it difficult to monitor
patients sufficiently closely to detect small volume relapse.
In this report we have presented long follow-up of a
cohort of patients with stage I seminoma managed by
orchidectomy and surveillance between 1983 and 1988; addi-
tionally we have performed a detailed histopathological
analysis of the primary tumours to investigate factors which
might predict recurrence.
Patients and methods
Of 113 patients managed by surveillance post-orchidectomy
for stage I seminoma the histopathology of the primary
tumour was available for detailed review in 103. These
patients all had radical inguinal orchidectomy performed
between 1983 and 1988. Their age range was 22-74 years
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(median 36 years). They have been followed for a median of
5 years and 2 months from orchidectomy (range 14 months
to 141 months).
Initial staging investigations prior to registering the patient
for surveillance always included thorough physical examina-
tion, assay of serum concentrations of the beta sub-unit of
human chorionic gonadotrophin (HCG) and alpha-fetoprotein
(AFP), CT scan of thorax abdomen and pelvis, lymphogram
and chest X-ray. The histopathology had always been
reviewed in the Department of Histopathology of The Royal
Marsden Hospital and the diagnosis of pure seminoma
confirmed. The method of surveillance is illustrated in Figure
1 and it can be seen that outpatient clinic assessments were
performed every 2 months during the first year after
orchidectomy, every 3 months during the second year, and
every 4 months during the third year and thereafter less
often. During the first year anteroposterior and oblique
abdominal X-rays were performed to follow retroperitoneal
lymph nodes, but lymphangiography was not repeated once
the quantity of contrast had diminished. Abdominal CT
scans were performed annually, or earlier if the patient had
symptoms suggestive of recurrence. Re-staging after diag-
nosis of relapse always included a CT scan of the thorax
abdomen and pelvis, and repeat assays of serum HCG and
AFP.
The histological review of the primary tumours was per-
formed by two pathologists (NA and CF). Sections were
examined for the following features:
(1) The pattern of seminoma (classical, fibrous bands,
angiomatoid).
(2) Syncytiotrophoblastic giant cells, necrosis, stromal
granulomas, lymphoid infiltrate, and Leydig cells (all
scored semiquantitatively).
(3) The cellular content of seminiferous tubules in adjacent
residual testis, assessed as: no cells; Sertoli cells only;
spermatogenic activity; in situ germ cell neoplasia
(extent recorded semiquantitatively).
(4) Invasion of spermatic cord, rete testis and vessels
(Blood or lymphatic). Lymphatic and vascular invasion
were sometimes difficult to distinguish and in these
cases invasion was deemed to be of lymphatics unless
red blood cells were also seen within the vessel.
Patients who relapsed with small volume disease < 5 cm in
diameter in the para-aortic nodes were then treated with
radiotherapy, using a 'dogleg' field encompassing para-aortic
and ipsilateral pelvic lymph nodes. Treatment was with 6-8
MEV linear accelerators trating anterior and posterior por-
tals daily to a midplane dose in the para-aortic region of
35 Gy in 18 fractions over 31 weeks restricting the dose to
'." Macmillan Press Ltd., 1992 Br. J. Cancer (1992), 65, 775-778776 A. HORWICH et al.
Seminoma stage I surveillance
Month 1 2 3 4 5 -6 7 8 9 10 11 12 18 24 30 36
OPD + + + + + + + + + + + }
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CT Scan + + +
U/S Abd. + +
Year 2 OPD q 2/12 U/S @ 18/12 CT @ 24/12
Year 3 OPD q 3/12 U/S @ 30/12 CT @ 36/12
Year 4 OPD q 4/12
Year 5 OPD q 6/12 CT @ 60/12
OPD = Outpatient visit. CXR = Chest X-ray. Abd. X-ray = Plain abdominal films to follow lymphogram.
CT = Computer tomographic. U/S = Ultrasound.
Figure 1 The Royal Marsden Hospital surveillance protocol for stage I testicular seminoma. OPD = Outpatient visit. CXR =
Chest X-ray. Abd. X-ray = Plain abdominal films to follow lymphogram. CT = Computer tomographic. U/S = Ultrasound.
the pelvis to 30 Gy in 15 fractions over 3 weeks. Patients
with large volume abdominal relapse, disseminated relapse,
or second relapse were treated with chemotherapy using single
agent carboplatin (Horwich et al., 1989), and then with
radiotherapy if the recurrence was localised. The radiation
technique was as described above with target volume restricted
to the post-chemotherapy mass and adjacent lymph nodes.
Statistics
Relapse free survival and survival were measured from the
date of registration. One patient developed a second primary
tumour of the head and neck. His seminoma had previously
recurred, however, for analysis of cause specific survival, he
was censored at the date of the second tumour. Differences
between relapse free survival curves in relation to histo-
pathological risk factors were analysed by the logrank
method.
Results
In 103 patients fully evaluated for histological analysis and
managed by surveillance for a median of 62 months after
orchidectomy for stage I seminoma, 17 have relapsed and the
probability of remaining relapse free at 5 years was 82%
(95% confidence interval, 74%-88%) (Figure 2). No patients
have died of germ cell tumour; three died of coincidental
disease. The site and extent of disease at relapse is shown in
Table I. Of the 17 patients recurrence was discerned with
small volume retroperitoneal nodes < 5 cm in diameter in 14.
One patient did not have a recurrence detected until his
para-aortic lymph node was 6 cm in diameter. Another
patient had para-aortic nodes more than 5 cm in diameter
associated with mass in the inguinal region at the upper part
of the ipsilateral inguinal canal, and a further patient
Table I Stage I seminoma: pattern of relapse on surveillance
Number of Treatment of
Relapse pattern patients relapse
P.A. nodes <2 cm 6 RT-5
CT-l a
P.A. nodes 2-5 cm 8 RT-7
CT + RT-lb
P.A. nodes >5 cm 1 CT + RT
P.A. nodes >5 cm and inguinal nodes I CT
P.A. nodes 2- cm and lung
1 CT
aPrior abdominal radiotherapy. b5 cm mass invading ureter.
RT = Radiotherapy. CT = Chemotherapy.
relapsed with multiple para-aortic lymph nodes 2-5 cm in
diameter associated with a solitary lung nodule assumed to
represent a metastasis. The nodule was no longer detectable
on post-chemotherapy scans.
Of the six patients relapsing with nodes <2 cm in diameter,
one had previously had radiotherapy because of a contra-
lateral testicular tumour diagnosed 11 years previously. The
other five were treated with radiotherapy. Of the eight patients
relapsing with nodes between 2 and 5 cm in diameter, seven
were treated with radiotherapy, but one patient with a 5 cm
mass obstructing the ureter was treated initially with
chemotherapy and then with radiotherapy. Thus 12 of the 17
relapsing patients were treated with radiotherapy alone, the
remaining five had chemotherapy alone (three) or
chemotherapy plus radiotherapy (two).
Of the 12 patients initially treated with radiotherapy for
recurrence, four developed a second recurrence in mediastinal
(three) or supraclavicular (one) nodes at 5, 6, 10 and 19
months after retroperitoneal node irradiation. All these four
were subsequently treated with carboplatin chemotherapy
and in three cases the site of relapse was treated with
radiotherapy also. Thus of the 17 patients relapsing from
surveillance, eight required chemotherapy at some stage
because of the extent of relapse and one required chemo-
therapy because of prior irradiation.
The analysis of the influence of histological parameters on
risk of relapse did not reveal any significant factors except
for lymphatic and vascular invasion (Figure 3). Four of 42
patients with neither lymphatic nor vascular invasion recur-
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Figure 2 Surveillance protocol for stage I testicular seminoma;
relapse-free survival in the 103 patients evaluable for analysis of
histopathological risk factors.
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Figure 3 Relapse-free survival with respect to microscopic
invasion of blood vessels and/or lymphatic vessels; 1 = neither
present, 2 = one of either blood vessel or lymphatic invasion,
3 = both blood vessel and lymphatic invasion.
red, nine of 53 patients with either lymphatic or vascular
invasion recurred and three of eight cases with both lym-
phatic and vascular invasion recurred (P = 0.05-trend). The
individual analyses of lymphatic invasion (Figure 4) and of
vascular invasion (Figure 5) showed that these conferred a
slightly higher relapse risk which did not reach statistical
significance.
Discussion
This report on surveillance for stage I seminoma of the testis
brings up-to-date our previous report (Duchesne et al., 1990).
The recurrence rate is slightly higher with longer follow-up
with an actuarial risk of recurrence of 18% by 5 years. The
predominant pattern of relapse was within 3 years of
orchidectomy and within para-aortic lymph nodes. The latest
relapse of our series was at 4 years post-orchidectomy and
the median follow-up of the 103 patients was just over 5
years.
A report on surveillance for stage I seminoma from the
Princess Margaret Hospital, Toronto (Thomas et al., 1989)
was based on 81 patients followed for a median of 19
months. At that time only three patients had relapsed at 3, 5
and 18 months after orchidectomy, however, with longer
follow-up, a higher recurrence rate has been observed close
to that noted in this report (G. Thomas, personal com-
munication). Similarly a Danish Study of surveillance for
stage I seminoma has found a very similar relapse rate
(Specht et al., 1991). It therefore, seems likely that even with
long follow-up less than 20% of patients with clinical stage I
seminoma will relapse and the benefit of surveillance is to
spare more than 80% of patients the possible side-effects of
adjuvant radiotherapy including peptic ulceration (Hamilton
et al., 1987) and induction of second malignancies (Hay et
al., 1984; Smith & Doll, 1982). On the other hand,
radiotherapy is usually very well tolerated; peptic ulcer
occurs very predominantly in patients with a prior history of
either ulceration or abdominal surgery (Hamilton et al.,
1987) and the risk of radiation induced second tumour
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Figure 4 Relapse-free survival with respect to microscopic
invasion of lymphatic vessels; 1 = invasion, 2 = no invasion.
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Figure 5 Relapse-free survival with respect to microscopic
invasion of blood vessels; 1 = invasion; 2 = no invasion.
appears extremely small (Fossa et al., 1990). Furthermore,
this report illustrates firstly the difficulty of identifying any
subgroup of patients with a particularly high or low risk of
relapse on surveillance and also the problems of carrying out
the policy safely since four of the 17 relapsing patients had
moderately bulky disease at relapse. It is therefore considered
that at present surveillance should remain a research protocol
and the routine management of the patient with stage I
seminoma should be with adjuvant retroperitoneal irradiation
post-orchidectomy. The pattern of recurrence in para-aortic
lymph nodes would suggest that the majority of patients may
not benefit from the pelvic component of the standard
'dogleg' field, though this conclusion would not apply to
those with a history of prior inguinal surgery (Mason et al.,
1991); a current Medical Research Council trial in stage I
testicular seminoma is prospectively comparing 'dogleg' with
para-aortic field radiotherapy following orchidectomy.
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